Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis

Inclusion Criteria: * Subject aged 18 to 75 years. * Diagnosis with distal subungual onychomycosis of the toenails that affects at least one great toe (target toenail). * Subject is willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol-specific procedures are performed. * Subject is able to complete the study, comply with study instructions, and take study product orally. * Sexually active non-lactating females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product and up to the first menses 60 days following the last dose of study product. * Women of childbearing potential must have a negative pregnancy test at enrollment. * Subject has screening laboratory parameters and ECG within the normal ranges unless considered to be not clinically relevant by the principal investigator. Exclusion Criteria: Subjects with any of the following conditions or characteristics will be excluded from study enrollment (ie, will not receive study product): * Subject has received an investigational drug within 4 weeks of the first dose of study product, or who are scheduled to receive an investigational drug other than the study product during the study. * Subject has participated in a clinical trial for the systemic treatment of onychomycosis of the toenails within 6 months prior to the first dose…